{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EPOCH+II&page=27",
    "query": {
      "intervention": "EPOCH II",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 887,
    "total_pages": 89,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EPOCH+II&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EPOCH+II&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T19:19:32.530Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04616963",
      "title": "Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hiv",
        "Hormone Therapy"
      ],
      "interventions": [
        {
          "name": "Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine Tenofovir Alafenamide 200/25 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2019-10-24",
      "completion_date": "2024-01-31",
      "has_results": false,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-11-17T19:19:32.530Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04616963"
    },
    {
      "nct_id": "NCT02135133",
      "title": "A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Idelalisib",
          "type": "DRUG"
        },
        {
          "name": "Ofatumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2014-06",
      "completion_date": "2020-10-06",
      "has_results": true,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-11-17T19:19:32.530Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02135133"
    },
    {
      "nct_id": "NCT05172258",
      "title": "Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Hypopharyngeal Squamous Cell Carcinoma",
        "Metastatic Laryngeal Squamous Cell Carcinoma",
        "Metastatic Oral Cavity Squamous Cell Carcinoma",
        "Metastatic Oropharyngeal Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Stage IV Hypopharyngeal Carcinoma AJCC v8",
        "Stage IV Laryngeal Cancer AJCC v8",
        "Stage IV Lip and Oral Cavity Cancer AJCC v8",
        "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2022-07-26",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-17T19:19:32.530Z",
      "location_count": 20,
      "location_summary": "Duarte, California • Irvine, California • Lancaster, California + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05172258"
    },
    {
      "nct_id": "NCT01866293",
      "title": "Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed or Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib (XL184)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2013-05-28",
      "completion_date": "2016-08-18",
      "has_results": true,
      "last_update_posted_date": "2017-08-30",
      "last_synced_at": "2026-11-17T19:19:32.530Z",
      "location_count": 5,
      "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rockville Centre",
          "state": "New York"
        },
        {
          "city": "Sleepy Hollow",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01866293"
    },
    {
      "nct_id": "NCT06656416",
      "title": "ALTO-100 in Bipolar Disorder With Depression (BD-D)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bipolar Disorder I or II With a Major Depressive Episode"
      ],
      "interventions": [
        {
          "name": "ALTO-100",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alto Neuroscience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 200,
      "start_date": "2024-10-02",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-17T19:19:32.530Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 48 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06656416"
    },
    {
      "nct_id": "NCT02913664",
      "title": "Risk Reduction for Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Cognitively Normal Older Adults",
        "Hypertension",
        "Subjective Cognitive Decline",
        "Family History of Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)",
          "type": "DRUG"
        },
        {
          "name": "Aerobic Exercise Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care",
          "type": "OTHER"
        },
        {
          "name": "Stretching Exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 513,
      "start_date": "2017-02-02",
      "completion_date": "2022-01-31",
      "has_results": false,
      "last_update_posted_date": "2022-02-15",
      "last_synced_at": "2026-11-17T19:19:32.530Z",
      "location_count": 4,
      "location_summary": "Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02913664"
    },
    {
      "nct_id": "NCT00110344",
      "title": "Research Study for Patients With Metastatic Renal Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Renal Cell"
      ],
      "interventions": [
        {
          "name": "Nexavar (Sorafenib, BAY43-9006)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2005-11",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2013-10-11",
      "last_synced_at": "2026-11-17T19:19:32.530Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00110344"
    },
    {
      "nct_id": "NCT04086485",
      "title": "Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastroenteropancreatico Tumors",
        "Neuroendocrine Tumors",
        "Neuroendocrine Neoplasms"
      ],
      "interventions": [
        {
          "name": "Lu-177-DOTATATE",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Ga dotatate scanning",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "FDG-PET scanning",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Amino Acid infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 56,
      "start_date": "2022-10-03",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-17T19:19:32.530Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04086485"
    },
    {
      "nct_id": "NCT05937152",
      "title": "A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "Eptinezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2025-01",
      "completion_date": "2025-11",
      "has_results": false,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-11-17T19:19:32.530Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05937152"
    },
    {
      "nct_id": "NCT04292535",
      "title": "Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Insulin",
        "Exercise"
      ],
      "interventions": [
        {
          "name": "Placebo into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "20 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "40 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "60 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "80 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "100 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        },
        {
          "name": "120 IU NovoLog Insulin aspart into the intranasal mucosa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michigan State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2018-06-15",
      "completion_date": "2020-02-20",
      "has_results": true,
      "last_update_posted_date": "2021-06-21",
      "last_synced_at": "2026-11-17T19:19:32.530Z",
      "location_count": 1,
      "location_summary": "East Lansing, Michigan",
      "locations": [
        {
          "city": "East Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04292535"
    }
  ]
}